HFSA 2026 at a glance
At HFSA 2026, the question is where competition in heart failure will shift next. From heart failure with preserved ejection fraction (HFpEF) and transthyretin amyloid cardiomyopathy (ATTR-CM) to precision cardiomyopathy treatments and connected care, HFSA 2026 is set to spotlight emerging opportunities for clinical differentiation.
📅 Build your schedule around the topics that matter most.
📥 Download the HFSA 2026_Preview_by_LucidQuest
Key Heart Failure Treatment Trends to Watch at HFSA 2026
HFpEF Treatment Expansion: MRAs, SGLT2 Inhibitors and Devices
Nonsteroidal mineralocorticoid receptor antagonists (MRAs), SGLT2 inhibitors, metabolic interventions and device-based approaches could broaden treatment strategies for HFpEF.
Earlier ATTR-CM Diagnosis and Treatment
Screening, amyloid imaging and disease-modifying therapies may reshape earlier diagnosis and longitudinal management of ATTR-CM.
Cardiac Myosin Inhibition: Aficamten and ACACIA-HCM
ACACIA-HCM readouts will examine aficamtens potential in nonobstructive hypertrophic cardiomyopathy (HCM).
Cardiogenic Shock: Mechanical Circulatory Support Strategies
Mechanical support timing, device selection and patient stratification are expected to influence treatment strategies in cardiogenic shock.
Competitor and Industry Signals at HFSA 2026
Alnylam, BridgeBio and Pfizer: ATTR-CM Competition
Vutrisiran, transthyretin (TTR) stabilization and evolving diagnostic pathways highlight increasing competition in ATTR-CM treatment.
Cytokinetics and Bristol Myers Squibb: HCM Treatment Differentiation
Aficamten data and HCM evidence-to-practice discussions could inform therapeutic differentiation in hypertrophic cardiomyopathy.
Affinia Therapeutics: AFTX-201 Gene Therapy for BAG3-Associated DCM
Investigational AFTX-201, through the UPBEAT trial, signals growing interest in gene-targeted treatment for BAG3-associated dilated cardiomyopathy (DCM).
Emerging Heart Failure Therapies: Tovinontrine, STM-01 and Cardiac Microcurrent
Tovinontrine Phase 2, STM-01 first-in-human cell therapy and cardiac microcurrent approaches warrant attention as emerging development directions.
Artificial Intelligence and Machine Learning at HFSA 2026
ARPA-H ADVOCATE: AI for Heart Failure Clinical Decision Support
AI-enabled approaches could advance clinical decision support and heart failure care workflows.
TAILORD and Remote Monitoring in Heart Failure
Digital interventions and remote monitoring may improve treatment optimisation and earlier identification of worsening heart failure.
What We Are Watching After HFSA 2026
- Whether tovinontrine demonstrates sufficient efficacy and safety to support further development.
- Whether aficamten strengthens the evidence for cardiac myosin inhibition in nonobstructive HCM.
- Whether AFTX-201, STM-01 and AI-enabled monitoring demonstrate clinically actionable benefits.
Download the HFSA 2026 Preview Report
Download LucidQuest’s HFSA 2026 Preview for deeper analysis of emerging heart failure therapies, clinical developments and competitive signals.
📅 Build your schedule around the sessions that matter most.
📥 Download the HFSA 2026_Preview_by_LucidQuest
Contact us for end-to-end conference coverage.
